Skip to Content

Apadaz Approval History

FDA Approved: Yes (First approved February 23, 2018)
Brand name: Apadaz
Generic name: acetaminophen and benzhydrocodone hydrochloride
Dosage form: Tablets
Previous Name: KP201
Company: KemPharm, Inc.
Treatment for: Pain

Apadaz (acetaminophen and benzhydrocodone hydrochloride) is an immediate release combination of acetaminophen and benzhydrocodone, a prodrug of the opioid agonist hydrocodone, indicated for the short-term management of acute pain.

Development History and FDA Approval Process for Apadaz

Feb 23, 2018Approval FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain
Jun 13, 2016FDA Issues Complete Response Letter for Apadaz New Drug Application
May  5, 2016Statement Regarding FDA Advisory Committee Meeting on KemPharm’s Abuse-Deterrent Product Candidate Apadaz
Apr 16, 2013KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
May 24, 2011KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.